Following the release of Neola Medical’s Q4 2024 report, Redeye Equity Research Analyst Gustaf Meyer interviewed CEO Hanna Sjöström to discuss key takeaways, the company’s progress toward the clinical phase, and the upcoming first clinical study on preterm born babies in Sweden.
Watch the full interview here:
Redeye also provided a research update, including a strengthened fair value range for Neola Medical.
Access the interview and additional insights from Redeye here: Redeye – Neola Medical